Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2019-04-03 | Edward M. Kaye, M.D. Class I Audit Committee member Compensation and Talent Committee member 2018 compensation: $281,656 Director Compensation section |
| 2020-03-26 | Edward M. Kaye, M.D. 70 Class I Audit Committee 17,500 Compensation and Talent Committee |
| 2021-04-07 | The following table sets forth the names of each member of our Board of Directors, their age, position, director class and committee membership as of April 1, 2021. Director Age Position/Class Audit Committee Compensation and Talent Committee Nominating and Governance Committee Science and Technology Committee Edward M. Kaye, M.D. 71 Class I ✓ ✓ |
| 2023-04-07 | The Audit Committee consists of directors Ms. Parshall (Chair), Dr. Kaye, Dr. Henderson and Mr. Smith. The Science and Technology Committee consists of directors Dr. Wierenga (Chair), Dr. Harrington, Dr. Henderson, and Dr. Kaye. |
| 2024-04-08 | Edward M. Kaye, M.D. has served as a member of our Board of Directors since May 2016. Dr. Kaye has served as the Chief Executive Officer of Stoke Therapeutics, Inc. since 2017. Previously, he served as President and Chief Executive Officer of Sarepta Therapeutics, Inc. from September 2016 to June 2017, interim Chief Executive Officer from March 2015 to September 2016 and Chief Medical Officer from June 2011 to April 2017. He also served on the company’s Board of Directors. Prior to joining Sarepta, Dr. Kaye was employed by Genzyme Corporation for ten years, holding various senior management positions, the most recent of which was Group Vice President of Clinical Development, in which he supervised clinical research in lysosomal storage disease programs and genetic neurological disorders. Dr. Kaye currently serves as a member of the Boards of Directors of the Massachusetts Biotechnology Council, Avidity Biosciences, Inc., and Stoke Therapeutics, Inc. Previously, Dr. Kaye served as Chief of Biochemical Genetics at Children’s Hospital of Philadelphia and Associate Professor of Neurology and Pediatrics at the University of Pennsylvania School of Medicine. Dr. Kaye serves as a Neurological Consultant at the Children’s Hospital of Boston and is on the editorial boards of a number of medical journals. He is also a member of several scientific advisory boards, including United Leukodystrophy Foundation, Spinal Muscular Atrophy Foundation, CureCMD, CureDuchenne and Prize4Life. Dr. Kaye received his medical education and pediatric training at Loyola University Stritch School of Medicine and University Hospital, child neurology training at Boston City Hospital, Boston University, and completed his training as a neurochemical research fellow at Bedford VA Hospital, Boston University. |
| Filing Date | Source Excerpt |
|---|---|
| 2012-06-13 | Edward M. Kaye, M.D., has served as our Senior Vice President and Chief Medical Officer since June 2011. |
| 2013-04-30 | Edward M. Kaye, M.D., 64, Senior Vice President, Chief Medical Officer |
| 2017-04-27 | Edward M. Kaye, M.D. has served as our President, Chief Executive Officer and a member of our Board since September 20, 2016. On April 24, 2017, Dr. Kaye informed the Board of his intention to resign as President and Chief Executive Officer upon the conclusion of his current employment term on September 20, 2017 or some other future date. Dr. Kaye will continue to serve as a Group I Director following his resignation as President and Chief Executive Officer. |
Source material: SEC submissions metadata and DEF 14A proxy filings from EDGAR. Last updated: 2026-03-22